241 related articles for article (PubMed ID: 23139279)
1. Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis.
Yu J; Peng R; Chen H; Cui C; Ba J
Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8146-53. PubMed ID: 23139279
[TBL] [Abstract][Full Text] [Related]
2. Vitreous proteomic analysis of proliferative vitreoretinopathy.
Yu J; Liu F; Cui SJ; Liu Y; Song ZY; Cao H; Chen FE; Wang WJ; Sun T; Wang F
Proteomics; 2008 Sep; 8(17):3667-78. PubMed ID: 18752205
[TBL] [Abstract][Full Text] [Related]
3. Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Wang ZY; Shen LJ; Zhao KK; Song ZM; Qu J
Ophthalmic Res; 2009; 42(3):138-40. PubMed ID: 19602911
[TBL] [Abstract][Full Text] [Related]
4. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
[TBL] [Abstract][Full Text] [Related]
5. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
6. Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis.
Li M; Li H; Jiang P; Liu X; Xu D; Wang F
Mol Biosyst; 2014 May; 10(5):1055-62. PubMed ID: 24556753
[TBL] [Abstract][Full Text] [Related]
7. Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade.
Symeonidis C; Papakonstantinou E; Androudi S; Georgalas I; Rotsos T; Karakiulakis G; Diza E; Dimitrakos SA
Cytokine; 2014 Jun; 67(2):71-6. PubMed ID: 24725542
[TBL] [Abstract][Full Text] [Related]
8. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
[TBL] [Abstract][Full Text] [Related]
9. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
10. The role of thrombin in proliferative vitreoretinopathy.
Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
[TBL] [Abstract][Full Text] [Related]
11. Prediction of proliferative vitreoretinopathy after retinal detachment surgery: potential of biomarker profiling.
Ricker LJ; Kessels AG; de Jager W; Hendrikse F; Kijlstra A; la Heij EC
Am J Ophthalmol; 2012 Aug; 154(2):347-354.e2. PubMed ID: 22541653
[TBL] [Abstract][Full Text] [Related]
12. Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy.
Velez G; Yang J; Li AS; Tsang SH; Bassuk AG; Mahajan VB
Sci Rep; 2019 May; 9(1):7608. PubMed ID: 31110225
[TBL] [Abstract][Full Text] [Related]
13. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
Kon CH; Occleston NL; Aylward GW; Khaw PT
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
[TBL] [Abstract][Full Text] [Related]
14. Vitreous levels of Lipocalin-2 on patients with primary rhegmatogenous retinal detachment.
Batsos G; Christodoulou E; Vartholomatos G; Galanis P; Stefaniotou M
PLoS One; 2019; 14(12):e0227266. PubMed ID: 31891637
[TBL] [Abstract][Full Text] [Related]
15. Adipokine levels in subretinal fluid from patients with rhegmatogenous retinal detachment.
Ricker LJ; Kijlstra A; Kessels AG; de Jager W; Hendrikse F; La Heij EC
Exp Eye Res; 2012 Jan; 94(1):56-62. PubMed ID: 22138416
[TBL] [Abstract][Full Text] [Related]
16. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M
Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976
[TBL] [Abstract][Full Text] [Related]
17. Altered Decorin Biology in Proliferative Vitreoretinopathy: A Mechanistic and Cohort Study.
Begum G; O'Neill J; Chaudhary R; Blachford K; Snead DRJ; Berry M; Scott RAH; Logan A; Blanch RJ
Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):4929-4936. PubMed ID: 30347087
[TBL] [Abstract][Full Text] [Related]
18. The upregulation of zinc finger protein 670 and prostaglandin D2 synthase in proliferative vitreoretinopathy.
Kuo HK; Chen YH; Huang F; Wu YC; Shiea J; Wu PC
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):205-13. PubMed ID: 25940552
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
Roldán-Pallarés M; Rollín R; Mediero A; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
Mol Vis; 2005 Jul; 11():461-71. PubMed ID: 16030497
[TBL] [Abstract][Full Text] [Related]
20. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Yamamoto S; Yamamoto T; Tsukahara I; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Jpn J Ophthalmol; 2002; 46(2):218-21. PubMed ID: 12062231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
